Relationship between magnetic resonance imaging features and miRNA gene expression in patients with glioblastoma multiforme

Chinese Medical Journal

Volumn 126, Issue 15, 2013, Pages 2881-2885

  Li, Wen Bin ^a   Chen, Hui Yuan ^a   Zhang, Wei ^b   Yan, Wei ^b   Shi, Rui ^a   Li, Shao Wu ^b   Jiang, Tao ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Gene expression; Glioblastoma; Magnetic resonance imaging; MicroRNAs

Indexed keywords

MICRORNA; MICRORNA 1282; MICRORNA 1300; MICRORNA 140; MICRORNA 221; MICRORNA 301A; MICRORNA 30E; MICRORNA 498; MICRORNA 524; MICRORNA 612; MICRORNA 888; MICRORNA 892A; MICRORNA 892B; MICRORNA 95; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; FOLLOW UP; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; MALE; MICROARRAY ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; RADIATION DOSE; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICROARRAY ANALYSIS; MICRORNAS; MIDDLE AGED; PROTEIN ARRAY ANALYSIS;

EID: 84880927414     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20130917     Document Type: Article

References (20)

1. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
2. Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003; 99: 467-473.
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
4. Helseth R, Helseth E, Johannesen TB, Langberg CW, Lote K, Rønning P, et al. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand 2010; 122: 159-167.
5. Sam GJ, Harpreet KS, Stijn VD, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008; 36: 154-158.
6. Lim LP, Glasner ME, Yekta S, Burge CB, Bartel DP. Vertebrate microRNA genes. Science 2003; 299: 1540.
7. Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res 2005; 334: 1351-1358.
8. Ricardo M, Sayyed KZ, Liu CG, Stein JL, van Wijnen AJ, Croce CM, et al. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res 2008; 68: 2773-2780.
9. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65: 6029-6033.
10. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 2008; 28: 5369-5380.
11. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64: 3753-3756.
12. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-436.
13. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008; 14: 2348-2360.
14. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513-10518.
15. Shai R M, Reichardt J K, Chen TC. Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas. Future Oncol 2008; 4: 525-534.
16. Li G, Zhang Z, Tu Y, Jin T, Liang H, Cui G, et al. Correlation of microRNA-372 upregulation with poor prognosis in human glioma. Diagn Pathol 2013; 8: 1.
17. Koshkin PA, Chistiakov DA, Chekhonin VP. Role of microRNAs in mechanisms of glioblastoma resistance to radio-and chemotherapy. Biochemistry 2013; 78: 325-334.
18. Nikaki A, Piperi C, Papavassiliou AG. Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy. Expert Opin Investig Drugs 2012; 21: 1475-1488.
19. Li WB, Tang K, Zhang W, Yan W, You G, Li SW, et al. Relationship between magnetic resonance imaging and molecular pathology in patients with glioblastoma multiforme. Chin Med J 2011; 124: 2589-2592.
20. Li WB, Tang K, Chen Q, Li S, Qiu XG, Li SW, et al. MRI manifestations correlate with survival of glioblastoma multiforme patients. Cancer Bio Med 2012; 9: 120-123.